Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

In the review article are provided the approaches to the therapy for improvement of prognosis in patients with peripheral and multifocal atherosclerosis which are available now; some limitations and a real situation are designated for the antithrombotic therapy in this category of patients. According to the clinical trial COMPASS the prospects of wide use of a combination of acetylsalicylic acid and a rivaroxsaban of 2.5 mg 2 times a day in the patients with chronic coronary heart disease and/or symptom peripheral atherosclerosis are designated.

Cite

CITATION STYLE

APA

Barbarash, O. L., & Kashtalap, V. V. (2019). Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization? Terapevticheskii Arkhiv, 91(12), 129–134. https://doi.org/10.26442/00403660.2019.12.000498

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free